DBVT News and Press, DBV Technologies S.A. From 01/09/20

Shares of DBV Technologies (NASDAQ: DBVT) are up 11% at 12:40 p.m. EST on positive long-term data for the biotech 's peanut allergy medication Viaskin Peanut. Children in the phase 3 Pepites clinical trial were able to continue on the drug in an extension study called People. After three y...

Applied Genetic Technologies (NASDAQ: AGTC ) +53%  on positive XLRP data . More news on: Applied Genetic Technologies Corporation, VBI Vaccines Inc., The Peck Company Holdings, Inc., Stocks on the move, Read more ...

Aptose Biosciences (APS CN) initiated with Overweight rating at Piper Sandler. Shares up  2%  premarket in U.S. (NASDAQ: APTO ). More news on: Aptose Biosciences Inc., BioDelivery Sciences International, Inc., BiomX Inc., Healthcare stocks news, Stocks on the move, , Read mor...

Gainers: CHS   +26.9% . DBVT   +21.6% . AGTC   +13.9% . NNVC   +10.3% . OTCQX:AKOM   +9.1% . More news on: Chico's FAS, Inc., DBV Technologies S.A., Applied Genetic Technologies Corporation, Stocks on the move, , News on ETFs Read more ...

DBV Technologies (NASDAQ: DBVT ) announces positive long-term results from the open-label extension study (( PEOPLE )) of its Phase 3 clinical trial, PEPITES , evaluating Viaskin Peanut in peanut-allergic children aged 4 - 11 years. More news on: DBV Technologies S.A., Healthcare stocks...

Montrouge, France, January 8, 2020 DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy Patients demonstrated durable, long-term clinical benefit with an additional...

Montrouge, France, January 2, 2020 DBV Technologies Announces Appointment of Ramzi Benamar as Chief Financial Officer DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Ramzi Be...

Editor's note: Seeking Alpha is proud to welcome Eugene Capital Advisors as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more » About DB...

Monthly information regarding the total number of voting rights and  total number of shares of the Company (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 * Total net =...

Montrouge, France, November 5, 2019 DBV Technologies to Present at the Stifel 2019 Healthcare Conference DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Kevin Trapp, Chief Commercial Off...